"[3] People who suffer from SIRVA typically require physical therapy, pain management medications, and in some severe cases, surgery.
[6][7] This inclusion allowed persons claiming an injury to seek compensation from a government fund set up under the program, while immunizing vaccine manufacturers and administrators from legal liability.
Since the Final Rule was promulgated, additional scientific research concluded that subdeltoid or subacromial bursitis and other shoulder lesions are "more likely to be the consequence of a poor injection technique (site, angle, needle size, and failure to take into account [a] patient's characteristics, i.e., sex, body weight, and physical constitution)," rather than "antigens or adjuvants contained in the vaccines that would trigger an immune or inflammatory response.
"[12]A number of contrary opinions were filed in response to the proposal, but the removal was made final on January 21, 2021.
[13] This removal was, in turn, reversed by a rule promulgated on April 21, 2021, restoring SIRVA to the table.